Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in May 2026.

Read a refresh of the top FDA news in breast cancer from May 2026, including several key approvals across ER-positive and triple-negative disease.

Experts highlight some top hematologic oncology data presented at ASCO 2026, including from key studies in multiple myeloma and diffuse large B-cell lymphoma.

Geoffrey Ku, MD, discusses data from HERIZON-GEA-01 showing zanidatamab plus tislelizumab benefits patients with HER2-positive GEA regardless of PD-L1 status.

The FDA has approved orally disintegrating nilotinib tablets for select patients with chronic myeloid leukemia.

Alan L. Ho, MD, PhD, discusses next steps for the evaluation of Oz-V in OPSCC based on its phase 2 efficacy in patients with treatment-refractory disease.

Alan L. Ho, MD, PhD, discusses safety data from a phase 2 trial of ozuriftamab vedotin in HPV-associated OPSCC.

Alan L. Ho, MD, PhD, discusses safety data from a phase 2 trial of ozuriftamab vedotin in HPV-associated OPSCC.

Ginger J. Gardner, MD, FACOG, discusses the importance of elevating the national conversation surrounding gynecologic cancers through collaborative efforts.

Michael J. Mauro, MD, discusses his approach to TKI use in chronic myeloid leukemia and how new FDA approvals inform his practice.

Drs Razavi and Ross note the evolution of ESR1 mutation–directed breast cancer management, including the role of genomic testing at metastatic recurrence.

The top 5 OncLive TV videos of the week cover insights in breast cancer, acute myeloid leukemia, bladder cancer, multiple myeloma, and melanoma.

Michael A. Postow, MD, discusses the importance of long-term multidisciplinary follow-up for patients with melanoma treated with ICIs.

Michael A. Postow, MD, discusses the evolving understanding of ICIs in melanoma and the unique toxicity profiles associated with these agents.

Michael Mauro, MD, details the FDA approval of the small-molecule formulation of dasatinib and other alternate TKI formulations in chronic myeloid leukemia.

Alan L. Ho, MD, PhD, discusses the unique elements of Oz-V that may contribute to its efficacy and tolerability in OPSCC.

Roisin E. O'Cearbhaill, MD, discusses a phase 1/2 trial assessing REGN5668 combined with other targeted agents in recurrent endometrial or ovarian cancer.

Michael J. Mauro, MD, discusses the variety of TKIs available for chronic myeloid leukemia management and how to navigate new formulations.

Jae Park, MD, discusses the importance and utility of MRD testing in the current acute lymphoblastic leukemia management field.

Jae Park, MD, discusses obe-cel in relapsed or refractory acute lymphoblastic leukemia and how new data are helping to shape its role.

Jae Park, MD, discusses recent developments for obe-cel and brexu-cel in acute lymphoblastic leukemia.

Lillian Rodich, MSPAS, MPH, highlights ways that medical oncologists can counsel patients with breast cancer about integrative medicine modalities.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of daratumumab plus VRd for the treatment of newly diagnosed, transplant-ineligible multiple myeloma.

Lutetium Lu 177 vipivotide tetraxetan–based therapy generated similar QOL outcomes compared with ADT plus an ARPI alone in patients with mHSPC.

Dr Schrag weighed in on where oncology stands today and previewed the goals she hopes to advance during her tenure as ASCO President in 2027-2028.

Dr Jhaveri discusses the evaluation of sacituzumab govitecan earlier in the HR-positive, HER2-negative metastatic breast cancer treatment paradigm.

Komal Jhaveri, MD, FACP, discusses lessons learned from the negative phase 3 ASCENT-07 trial in hormone receptor–positive, HER2-negative breast cancer.

Dr Falchi discusses why the FDA approval of epcoritamab plus lenalidomide/rituximab is clinically meaningful for relapsed/refractory follicular lymphoma.

The top 5 OncLive TV videos of the week cover insights in leukemia, lung cancer, multiple myeloma, indolent systemic mastocytosis, and pancreatic cancer.

Saad Z. Usmani, MD, MBA, FACP, FASCO, is renowned leader whose work has helped redefine treatment standards and extend the lives of patients worldwide.